203 related articles for article (PubMed ID: 35646685)
1. A Combination of Cytokine-Induced Killer Cells With PD-1 Blockade and ALK Inhibitor Showed Substantial Intrinsic Variability Across Non-Small Cell Lung Cancer Cell Lines.
Li Y; Sharma A; Wu X; Weiher H; Skowasch D; Essler M; Schmidt-Wolf IGH
Front Oncol; 2022; 12():713476. PubMed ID: 35646685
[TBL] [Abstract][Full Text] [Related]
2. Increase in Efficacy of Checkpoint Inhibition by Cytokine-Induced-Killer Cells as a Combination Immunotherapy for Renal Cancer.
Dehno MN; Li Y; Weiher H; Schmidt-Wolf IGH
Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349280
[TBL] [Abstract][Full Text] [Related]
3. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells.
Li Y; Sharma A; Hoffmann MJ; Skowasch D; Essler M; Weiher H; Schmidt-Wolf IGH
Front Immunol; 2024; 15():1268652. PubMed ID: 38558822
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients.
Hong S; Chen N; Fang W; Zhan J; Liu Q; Kang S; He X; Liu L; Zhou T; Huang J; Chen Y; Qin T; Zhang Y; Ma Y; Yang Y; Zhao Y; Huang Y; Zhang L
Oncoimmunology; 2016 Mar; 5(3):e1094598. PubMed ID: 27141355
[TBL] [Abstract][Full Text] [Related]
5. Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer.
Chen J; Chen Y; Feng F; Chen C; Zeng H; Wen S; Xu X; He J; Li J
J Thorac Dis; 2018 Dec; 10(12):6711-6721. PubMed ID: 30746216
[TBL] [Abstract][Full Text] [Related]
6. PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines.
Li Y; Sharma A; Bloemendal MWJR; Schmidt-Wolf R; Kornek M; Schmidt-Wolf IGH
Oncol Lett; 2021 Aug; 22(2):613. PubMed ID: 34257721
[TBL] [Abstract][Full Text] [Related]
7. Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
Han Y; Mu D; Liu T; Zhang H; Zhang J; Li S; Wang R; Du W; Hui Z; Zhang X; Ren X
Thorac Cancer; 2021 Jan; 12(2):145-152. PubMed ID: 33150733
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Complete Response to Nivolumab in a Patient With Programmed Cell Death 1 Ligand 1-Positive and Multiple Gene-Driven Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Resistant Lung Adenocarcinoma.
Dong W; Lei P; Liu X; Li Q; Cheng X
Front Immunol; 2021; 12():686057. PubMed ID: 34804000
[TBL] [Abstract][Full Text] [Related]
9. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt.
Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF
J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823
[TBL] [Abstract][Full Text] [Related]
10. [Effects of humanized interleukin 21 on anti-leukemic activity of cytokine induced killer cells and the mechanism].
Zhao N; Zhao MF; Rajbhandary S; Lu WY; Zhu HB; Xiao X; Deng Q; Li YM
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):823-8. PubMed ID: 23384903
[TBL] [Abstract][Full Text] [Related]
11. [Effects and mechanism on anti-leukemic activity of cytokine-induced killer cells with an endogenous expression of interleukin-21].
Zhao N; Zhao MF; Rajbhandary S; Lu WY; Zhu HB; Ma L; You Q; Xiao X; Deng Q; Li YM
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(4):293-9. PubMed ID: 23578511
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
Du P; Hu T; An Z; Li P; Liu L
Cancer Sci; 2020 Jun; 111(6):1887-1898. PubMed ID: 32227409
[TBL] [Abstract][Full Text] [Related]
13. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
14. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
[TBL] [Abstract][Full Text] [Related]
15. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3.
Koh J; Jang JY; Keam B; Kim S; Kim MY; Go H; Kim TM; Kim DW; Kim CW; Jeon YK; Chung DH
Oncoimmunology; 2016 Mar; 5(3):e1108514. PubMed ID: 27141364
[TBL] [Abstract][Full Text] [Related]
16. Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients.
Zhang L; Wang J; Wei F; Wang K; Sun Q; Yang F; Jin H; Zheng Y; Zhao H; Wang L; Yu W; Zhang X; An Y; Yang L; Zhang X; Ren X
Oncotarget; 2016 Jul; 7(28):43604-43615. PubMed ID: 27283895
[TBL] [Abstract][Full Text] [Related]
17. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
18. Effect of PF-02341066 and radiation on non-small cell lung cancer cells.
Tumati V; Kumar S; Yu L; Chen B; Choy H; Saha D
Oncol Rep; 2013 Mar; 29(3):1094-100. PubMed ID: 23254764
[TBL] [Abstract][Full Text] [Related]
19. Alterations in PD-L1 Expression Associated with Acquisition of Resistance to ALK Inhibitors in ALK-Rearranged Lung Cancer.
Kim SJ; Kim S; Kim DW; Kim M; Keam B; Kim TM; Lee Y; Koh J; Jeon YK; Heo DS
Cancer Res Treat; 2019 Jul; 51(3):1231-1240. PubMed ID: 30653748
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]